

Vyndamax™ (tafamidis)

What is Vyndamax?

Vyndamax is an oral TTR stabilizer developed for treating patients with transthyretin amyloidosis (ATTR) who have heart involvement (cardiomyopathy). ATTR amyloidosis is caused by the misfolding and subsequent build-up of a protein called transthyretin – or TTR for short. This build-up of TTR in tissues and organs stops them from working properly. There are two different types of ATTR amyloidosis: one is caused by an inherited mutation, called hereditary ATTR (hATTR), and the other which is not inherited, called wildtype ATTR (ATTRwt).

How does Vyndamax work?

Vyndamax is a drug that acts as a TTR stabilizer. Vyndamax stabilizes TTR by acting as a ‘chaperone molecule’, which means it binds to TTR and helps it form correctly. By stabilizing TTR and reducing the rate at which TTR misfolds, Vyndamax has the potential to limit amyloid formation and subsequently slow the progression of the disease.

How is Vyndamax administered?

Vyndamax is 61mg pill or capsule taken by mouth once a day.

Clinical trial evidence for Vyndamax

In the randomized, double-blind, placebo-controlled Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Phase III clinical trial, 264 ATTR-CM patients received tafamidis (20mg or 80mg) daily for 30 months. Results from the trial have shown that, compared to those on placebo, patients who received tafamidis:

- Saw statistically significant reduction in all-cause mortality
- Saw statistically significant reduction in the frequency of cardiac related hospitalizations
- Had significantly greater exercise capacity and quality of life



Side effects of Vyndamax

For more information on side effects, you can refer to the Vyndamax website [here](#).

Availability of Vyndamax

Vyndamax was approved by the FDA on May 6, 2019 for the treatment of ATTR cardiomyopathy (ATTR-CM) in the United States.

Insurance coverage of Vyndamax will vary depending on the particular plan. If insurance does not provide enough coverage, there are additional programs that can be looked in to. This includes Pfizer's patient prescription assistance program, Pfizer RxPathways. You can learn more about this program on Pfizer's website through the following link:

<https://www.pfizer.com/purpose/patient-assistance-programs>

More Information

For more information you can visit us at www.arci.org. If you have further questions, you can contact us by phone at 617-467-5170 or by email at support@arci.org.